Taysha Gene Therapies price target raised to $13 from $7 at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies (TSHA) to $13 from $7 and keeps an Overweight rating on the shares. After having attended the IRSF Rett Syndrome Scientific Meeting and spent additional time with Taysha management, the firm has “very high conviction” that the TSHA-102 pivotal trial will succeed, the analyst tells investors. Following data and regulatory path updates, the firm is increasing its view of the odds of success for TSHA-102 to 70% from 35%, the analyst noted.